Active	Status	Sponsor type	Region	Phase	Filter
18 Active 26 Inactive 44 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dummer, Reinhard
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Recruiting	2/3	420	Europe, Canada, US, RoW	IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome	IDEAYA Biosciences	Metastatic Uveal Melanoma	01/27	01/28
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Active, not recruiting	2	220	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034	Agenus Inc.	Advanced Melanoma	05/28	05/28
DUNCAN, NCT04362722 / 2020-003299-42: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients	Recruiting	2	40	Europe	L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa	Philogen S.p.A., Philogen S.p.A.	Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell	09/24	09/24
NCT04679480: Anti-PD1-antibody and Pulsed HHI for Advanced BCC	Active, not recruiting	2	20	Europe	Cemiplimab Injection [Libtayo], Sonidegib	Reinhard Dummer, Sanofi, Sun Pharmaceutical Industries Ltd	Basal Cell Carcinoma	12/24	12/24
NCT05120596: First in Human Study of T3P-Y058-739 (T3P)	Recruiting	1/2	100	Europe	Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT)	T3 Pharmaceuticals AG	Advanced Solid Tumor	02/26	10/26
GDFATHER, NCT04725474 / 2020-002103-19: First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer	Active, not recruiting	1/2	274	Europe	visugromab (CTL-002)	CatalYm GmbH, CatalYm GmbH	Solid Tumor, Adult	10/25	10/27
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors	Recruiting	1	275	Europe, Canada, US	PF-08046049	Seagen Inc.	Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma	11/26	11/27
Navarini, Alexander A
Neo-DREAM, NCT03567889 / 2021-003064-27: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients	Recruiting	3	186	Europe, US	Daromun, Surgery, Adjuvant therapy	Philogen S.p.A., Philogen S.p.A.	Melanoma Stage IIIB/C	06/24	06/26
NCT06319794: Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis	Recruiting	2	40	Europe	Bimiralisib	TORQUR	Actinic Keratosis	12/24	12/24
NCT05848453: Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses	Completed	1	24	Europe	BAP5191	Bacoba AG, University Hospital, Basel, Switzerland, Swiss TPH, Basel, Switzerland	Healthy	03/24	03/24
IRASPEN, NCT04359394: International Rare And Severe Psoriasis Expert Network	Recruiting	N/A	180	Europe, RoW	biological sampling, Phenotypic description, Photography	University Hospital, Basel, Switzerland, Boehringer Ingelheim	Pustular Psoriasis (PP)	12/30	12/30
Mueller, Philipp
No trials found